With No­vavax vac­cine deal un­der its belt, SK Bio­science plots out March IPO on the Ko­re­an ex­change

It pays to be in the Covid-19 vac­cine man­u­fac­tur­ing busi­ness.

Short­ly af­ter it an­nounced an ex­pand­ed deal to pro­duce 40 mil­lion dos­es of No­vavax’s Covid-19 jab, SK Bio­science, an off­shoot of Ko­rea’s SK Group, un­veiled plans to launch an ini­tial pub­lic of­fer­ing on the Ko­re­an Ex­change in March with the goal of ex­pand­ing its con­tract man­u­fac­tur­ing busi­ness and build­ing on ex­ist­ing vac­cine de­vel­op­ment plat­forms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.